NEW YORK (dpa-AFX Broker) - The analyst firm Jefferies left its rating for Dermapharm at "Buy" with a price target of 65 euros after preliminary annual figures. Overall, the drugmaker's key figures were in line with average market expectations, analyst Alexander Thiel wrote in an initial assessment published on Tuesday. The outlook for 2023 appears conservative./edh/la

Original publication date: 03/14/2023 / 03:51 / ET

First disclosure of original study: 14.03.2023 / 03:51 / ET

-----------------------

dpa-AFX Broker - Trader News from dpa-AFX

-----------------------